| NCT ID | NCT07416513 |
| Status | Recruiting |
| Phase | — |
| Sponsor | European Institute of Oncology |
| Condition | Cancer Diagnosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-05-14 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2025-05-14 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The target population includes cancer patients, caregivers, family members, healthcare providers and mental health specialists, who will be the primary end-users of the Althea platform. For patients, survivors, caregivers, and family members, the sample variables include age, gender, type and stage of disease, and time since the first diagnosis. The healthcare professionals that will be involved in this study are those who attend to oncological patients, with sample variables such as age, gender, professional role, and prior experience and training in oncology or psycho-oncology.
Eligibility Criteria
Inclusion Criteria: HEALTHCARE PROFESSIONALS: * Healthcare professionals actually working in oncology and/or psychooncology; * Teachers of paediatric cancer patients. ADULT POPULATION: * Patients with a current or previous cancer diagnosis * Adequate language proficiency, * Able to provide informed consent; PAEDIATRIC POPULATION: * Older than 12 years of age; * Patients with a current or previous cancer diagnosis; * Adequate language proficiency; * Legal guardians of paediatric cancer patients able to provide informed consent. CAREGIVERS: * Caregivers and/or family members of cancer patients who lived or assist the loved ones with a current or previous cancer diagnosis in the cancer journey; * Adequate language proficiency; * Able to provide informed consent; * Caregivers and/or family members of paediatric cancer patients under 12 years of age. Exclusion Criteria: * Healthcare professionals with limited oncology patient contact; * Insufficient knowledge of the local language; * Severe cognitive impairment, and/or mental disorders that prohibited their participation in the study or inadequate verbal skills that may render them incapable of informed consent (as evaluated by the clinician); * Inability to understand the study materials (as evaluated by the clinician); * Physical or psychological impairment that prohibits their participation in focus groups (as evaluated by the clinician).
Contact & Investigator
Gabriella Pravettoni, MD
PRINCIPAL INVESTIGATOR
European Institute of Oncology
Frequently Asked Questions
Who can join the NCT07416513 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, studying Cancer Diagnosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07416513 currently recruiting?
Yes, NCT07416513 is actively recruiting participants. Contact the research team at gabriella.pravettoni@ieo.it for enrollment information.
Where is the NCT07416513 trial being conducted?
This trial is being conducted at Caen, France, Homburg, Germany, Milan, Italy, Vilnius, Lithuania and 1 additional location.
Who is sponsoring the NCT07416513 clinical trial?
NCT07416513 is sponsored by European Institute of Oncology. The principal investigator is Gabriella Pravettoni, MD at European Institute of Oncology. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.